Phase I Study of HRS-3005 in B-cell Malignancies

NCT07556822 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancy

Interventions

DRUG: HRS-3005

Sponsor

Jiangsu HengRui Medicine Co., Ltd.